[1]王海银,丛鹂萱,谢春艳,等.我国创新药品医保支付改革的进展及思考[J].卫生经济研究,2021,38(1):47-49.
　WANG Hai-yin,CONG Li-xuan,XIE Chun-yan,et al.Progress and Consideration on the Medical Insurance Payment Reform for Innovative Drugs in China[J].Journal Press of Health Economics Research,2021,38(1):47-49.
点击复制

我国创新药品医保支付改革的进展及思考
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年1期
页码:
47-49
栏目:
医保天地
出版日期:
2021-01-07

文章信息/Info

Title:
Progress and Consideration on the Medical Insurance Payment Reform for Innovative Drugs in China
作者:
王海银1; 丛鹂萱1; 谢春艳1; 王美凤1; 刘 昕1; 金春林1
1.上海市卫生和健康发展研究中心，上海 200032
Author(s):
WANG Hai-yin; CONG Li-xuan; XIE Chun-yan; WANG Mei-feng; LIU Xin; JIN Chun-lin
Shanghai Health Development Research Center, Shanghai 200032,China
关键词:
创新药品; 医保支付; 谈判准入; 可及性
Keywords:
innovative drugs;  insurance payment;  negotiation access;  accessibility
分类号:
R19；R95
文献标志码:
A
摘要:
创新药品给患者带来了更多的健康获益，但部分创新药品价格高昂，患者自付负担较重。医保支付通过目录准入、支付方式、结算框架等方面，影响创新药品的可及性。本文归纳了我国当前创新药品医保支付改革的实践进展，提出思考建议：探索分类评价准则，完善创新药品谈判机制；探索引入条件准入协议，重视真实世界数据证据；充分整合慈善基金，完善创新药品安全网救助机制； 鼓励商业保险参与，支持DTP分期支付等市场行为，提高创新药品的可及性。
Abstract:
Innovative drugs can bring more health benefit to patients,but some of them are expensive and patient have a heavy burden by paying cash. Insurance payment affects the accessibility of innovative drugs through the catalogue access,payment ,settlement framework and so on.This paper summarizes the practical progress of current innovative drug health insurance payment reform,and puts forward some suggestions:explore the classified evaluation criteria,improve the innovative drug negotiation mechanism;explore the agreement of conditional access agreements,pay attention to real-world data evidence;fully integrate charitable funds,improve the innovative drug safety net relief mechanism;encourage commercial insurance to participate,support market behaviors such as DTP payment,and improve the accessibility of innovative drugs.

参考文献/References:

[1] 宁艳阳，蔡江南.医疗创新谁来买单[J].中国卫生,2019（10）：92-95.
[2] 李赛赛，徐伟，王煜昊，等.创新药物医保目录准入研究[J].卫生经济研究，2019，36（10）：40-43.
[3] 顾雪非，刘小青. 从数量到价值:医保支付如何驱动医疗卫生体系整合[J].卫生经济研究，2020，37（1）：7-10.
[4] 刘敏.创新药大变局[J].中国医院院长，2019（1）：48-49.
[5] 丁锦希.医保药品谈判准入彰显社会治理机制——国家医保药品准入首次谈判的七个亮点[J].中国医疗保险，2017（8）：21-22.
[6] Tang M,Song P,He J.Progress on drug pricing negotiations in China[J].BioScience Trends,2019,13(6):1-4.
[7] 贺小林，梁鸿，刘军帅.青岛市高值药品救助政策的实践与创新[J].中国医疗保险，2014（8）：36-38.
[8] 常峰，张舰云，崔鹏磊，等.国内典型地区特药谈判模式总结及启示[J].现代商贸工业，2017，38（9）：48-51.
[9] 任磊，蒋蓉，袁韩时弼，等.台湾地区创新药品支付标准管理体系研究——基于阿哌沙班片的实证分析[J].中国医疗保险,2018（6）：63-67.
[10] 王思敏，徐伟，崔子丹，等.价值医疗导向的医保支付方式初探——以中美典型按价值付费项目为例[J].卫生经济研究，2019，36（2）：9-12.
[11] 张笑雨.医疗金融兴起，买药步入“分期付款”时代[J].中国药店，2018（7）：30-31.
[12] 王锦银.医保支付方式变革对DTP药房的影响[J].中国药店，2019（9）：88-90.
[13] 魏靖哲，蒋蓉，孙圆圆，等.意大利创新药物条件准入协议政策分析及对我国的启示[J].中国新药杂志，2019（4）：385-389.
[14] Panteli D,Arickx F,Cleemput I, et al.Pharmaceutical regulation in 15 European countries[J].Review,2016,18(5):27-49.
[15] 朱越，蒋蓉，袁韩时弼，等.基于实证分析的我国药品支付标准制定研究[J].卫生经济研究，2018（1）：50-55.

相似文献/References:

[1]田文华.上海市医保支付改革方案的设计和模拟分析[J].卫生经济研究,2018,(02):22.
[2]梁 冰,王前强,陈凤磊,等.国家谈判药品对综合医院医保管理的影响及对策[J].卫生经济研究,2020,(05):42.
　LIANG Bing,WANG Qian-qiang,CHEN Feng-lei,et al.Impact of National Negotiation Drugs on Medical Insurance Management in General Hospitals and Countermeasures[J].Journal Press of Health Economics Research,2020,(1):42.
[3]路娜娜,徐 伟,杜雯雯,等.美国互联网医疗服务的医保支付政策及启示[J].卫生经济研究,2020,(10):37.
　LU Na-na,XU Wei,DU Wen-wen,et al.Medical Insurance Payment Policy and Enlightenment of American Internet Medical Service[J].Journal Press of Health Economics Research,2020,(1):37.
[4]于保荣.DRG与DIP的改革实践及发展内涵[J].卫生经济研究,2021,38(1):4.
　YU Bao-rong.Reform Practice and Development Connotation of DRG and DIP[J].Journal Press of Health Economics Research,2021,38(1):4.
[5]陈志鹏,杨金侠.医保支付促进慢性病管理的国际经验及启示[J].卫生经济研究,2021,38(2):38.
　CHEN Zhi-peng,YANG Jin-xia.International Experience and Inspiration of Medical Insurance Payment on Promoting Chronic Disease Management[J].Journal Press of Health Economics Research,2021,38(1):38.
[6]薛丽娜,王世贞,毛宗福.我国城镇职工医保的门诊统筹进展及改革思考[J].卫生经济研究,2021,38(10):30.
　XUE Li-na,WANG Shi-zhen,MAO Zong-fu.Thoughts on Outpatient Co-ordination Development and Reform of Urban Employee Medical Insurance in China[J].Journal Press of Health Economics Research,2021,38(1):30.
[7]裘凯音,王 佳,王伟红,等.市级统筹背景下DRG付费的公平性研究[J].卫生经济研究,2021,38(12):33.
　QIU Kai-yin,WANG Jia,WANG Wei-hong,et al.Research on the Fairness of DRG Payment at the Municipal Level[J].Journal Press of Health Economics Research,2021,38(1):33.
[8]陈姬雅,娄雪萍,王蓉蓉,等.数字医疗推动DRG点数支付改革的精细化管理[J].卫生经济研究,2021,38(12):72.
　CHEN Ji-ya,LOU Xue-ping,WANG Rong-rong,et al.Digital Medical Promotes Fine Management of DRG Point Payment Reform[J].Journal Press of Health Economics Research,2021,38(1):72.
[9]金春林,彭 颖,王海银.深化医疗服务价格改革的内涵与思考[J].卫生经济研究,2022,39(1):7.
　JIN Chun-lin,PENG Ying,WANG Hai-yin.The Connotation and Thinking of Deepening the Medical Service Price Reform[J].Journal Press of Health Economics Research,2022,39(1):7.
[10]伍 琳,陈永法.医保支付激励整合医疗服务的逻辑与实现路径[J].卫生经济研究,2022,39(1):31.
　WU Lin,CHEN Yong-fa.The Logic and Pathway of Medical Insurance Payment Incentivizing Integrated Medical Service[J].Journal Press of Health Economics Research,2022,39(1):31.

更新日期/Last Update: 2021-01-07